American Journal of Ophthalmology
Volume 146, Issue 2 , Pages 285-291.e1 , August 2008

Fluocinolone Acetonide Sustained Drug Delivery Device for Chronic Central Retinal Vein Occlusion: 12-Month Results

,Accepted 31 March 2008.

References 

  1. Bearelly S, Fekrat S. Controversy in the management of retinal venous occlusive disease. Int Ophthalmol Clin. 2004;44:85–102
  2. CVOS Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486–491
  3. Cekic O, Chang S, Tseng J, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina. 2005;25:846–850
  4. Bashshur Z, Ma'luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. 2004;122:1137–1140
  5. Degenring R, Kamppeter B, Kreissig I, et al. Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta Ophthalmol Scand. 2003;81:548–550
  6. Ip M, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004;122:1131–1136
  7. Jonas J. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular disease. Acta Ophthalmol Scand. 2005;83:645–663
  8. Jonas J, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005;24:587–611
  9. Jonas JB. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:782–783
  10. Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to central vein occlusion. Acta Ophthalmol Scand. 2005;83:71–75
  11. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003;136:419–425
  12. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol. 2005;139:860–866
  13. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion. Retina. 2007;27:1004–1012
  14. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch of Ophthalmol. 2003;121:279–282
  15. National Eye Institute. The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema Clinical Studies Database, 2007. www.nei.nih.gov/netrials/viewStudyweb.aspx?id=99Accessed: August 21, 2007
  16. Jaffe GJ, Ben-nun J, Gou H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–2033
  17. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192–1198
  18. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Ophthalmology. 2006;113:1020–1027
  19. Kupperman BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309–317
  20. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol. 2004;137:758–760
  21. Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema (Risk factors for development and duration after treatment). J Cataract Refract Surg. 2007;33:1550–1558

PII: S0002-9394(08)00256-0

doi: 10.1016/j.ajo.2008.03.025

American Journal of Ophthalmology
Volume 146, Issue 2 , Pages 285-291.e1 , August 2008

Article Tools

* Image Usage & Resolution